Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Therapie
|
March 4, 2026
Validation of in-hospital diagnosis codes to identify skin ulcers in healthcare databases: A correspondence. Response of authors
Clément Jambon-Barbara, Coline Brossat, Alex Hlavaty, et al.
Therapeutic Advances in Neurological Disorders
|
September 18, 2024
Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
Charles Khouri, Alex Hlavaty, Bruno Revol, et al.
Eclinicalmedicine
|
September 2, 2025
Complexity of interstitial lung disease disproportionality signal analysis in pharmacovigilance databases
Romane Freppel, Alex Hlavaty, Imen Bari, et al.
Therapie
|
December 6, 2023
The Christmas adverse event syndrome: An analysis of the WHO pharmacovigilance database
Alex Hlavaty, Matthieu Roustit, Marc Manceau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 20, 2025
Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database
Alex Hlavaty, Loubna Dari, Jean-Luc Cracowski, et al.
Clinical Pharmacology and Therapeutics
|
December 21, 2025
The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
The European Respiratory Journal
|
September 30, 2021
Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database
Charles Khouri, Alex Hlavaty, Matthieu Roustit, et al.
Clinical Pharmacology and Therapeutics
|
May 5, 2026
Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance"
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
June 6, 2023
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
Orhon Pauline, Marion Robert, Claire Bernardeau, et al.
Journal of Clinical Epidemiology
|
May 23, 2026
Changes in estimands and prevalence of discrepancies in conclusions under the two-trial paradigm: a systematic review
Alex Hlavaty, Clément Jambon-Barbara, Marc Manceau, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Therapie
|
March 4, 2026
Validation of in-hospital diagnosis codes to identify skin ulcers in healthcare databases: A correspondence. Response of authors
Clément Jambon-Barbara, Coline Brossat, Alex Hlavaty, et al.
Therapeutic Advances in Neurological Disorders
|
September 18, 2024
Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
Charles Khouri, Alex Hlavaty, Bruno Revol, et al.
Eclinicalmedicine
|
September 2, 2025
Complexity of interstitial lung disease disproportionality signal analysis in pharmacovigilance databases
Romane Freppel, Alex Hlavaty, Imen Bari, et al.
Therapie
|
December 6, 2023
The Christmas adverse event syndrome: An analysis of the WHO pharmacovigilance database
Alex Hlavaty, Matthieu Roustit, Marc Manceau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 20, 2025
Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database
Alex Hlavaty, Loubna Dari, Jean-Luc Cracowski, et al.
Clinical Pharmacology and Therapeutics
|
December 21, 2025
The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
The European Respiratory Journal
|
September 30, 2021
Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database
Charles Khouri, Alex Hlavaty, Matthieu Roustit, et al.
Clinical Pharmacology and Therapeutics
|
May 5, 2026
Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance"
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
June 6, 2023
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
Orhon Pauline, Marion Robert, Claire Bernardeau, et al.
Journal of Clinical Epidemiology
|
May 23, 2026
Changes in estimands and prevalence of discrepancies in conclusions under the two-trial paradigm: a systematic review
Alex Hlavaty, Clément Jambon-Barbara, Marc Manceau, et al.
Page
of 3